A review article discussing current and emerging therapies for chronic cutaneous GVHD, including extracorporeal photopheresis, and second-line drugs targeting T cells, B cells, and inflammatory cytokines. The authors discuss the growing knowledge of the pathogenesis of cutaneous GVHD, focusing on the role of B cells and the utility of rituximab therapy. The authors also introduce a clinical algorithm to guide clinicians in treating limited and extensive cutaneous GVHD, as well as steroid refractory or persistent cutaneous GVHD where steroid sparing is indicated.
Choose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
Emerging Therapies for Chronic Cutaneous GVHD
Apr 2013